Influence of glucocorticoid treatment on trabecular bone score and bone remodeling regulators in early rheumatoid arthritis.
Bone mineral density
Glucocorticoids
Rheumatoid arthritis
Trabecular bone score
Wnt signaling
Journal
Arthritis research & therapy
ISSN: 1478-6362
Titre abrégé: Arthritis Res Ther
Pays: England
ID NLM: 101154438
Informations de publication
Date de publication:
06 07 2021
06 07 2021
Historique:
received:
10
03
2021
accepted:
23
06
2021
entrez:
7
7
2021
pubmed:
8
7
2021
medline:
14
8
2021
Statut:
epublish
Résumé
Glucocorticoids (GC) modulate several regulators involved in the pathogenesis of bone changes in rheumatoid arthritis (RA). Trabecular bone score (TBS) allows the indirect assessment of bone quality. The aim of this study was to investigate the effects of GC on TBS and serum levels of bone turnover regulators in patients with recent-onset RA. Forty-seven subjects with recent-onset RA (< 6 months) were classified in two groups, low (lGC) and high (hGC) glucocorticoids, according to glucocorticoid dose regimens. Bone mineral density (BMD), TBS, and circulating Dickkopf-1 (Dkk1), sclerostin, osteoprotegerin (OPG), and RANK-L were evaluated at baseline and 6 and 12 months. BMD significantly declined after 12 months with no significant difference between the lGC and hGC group, whereas TBS decreased in the hGC group only. Circulating OPG decreased during the follow-up period, the reduction being significantly greater in hGC group; conversely, sclerostin and RANK-L serum increased, in a significantly greater extent in the hGC group. TBS inversely correlated with sclerostin, RANK-L, and Dkk1 circulating levels whereas directly correlated with OPG circulating levels. GC cumulative dose showed an inverse relationship with BMD in both the hGC and lGC groups; TBS values showed an inverse relationship with GC cumulative dose in the hGC group only. GC cumulative dose was associated to higher sclerostin and lower OPG serum levels. TBS did not correlate with disease activity whereas BMD was inversely related to disease activity. In early RA, GC exposure contributes to the reduction of BMD and affects bone quality depending on dose regimens. TBS could be a useful tool to evaluate the negative effect of GC on bone microarchitecture. This study was ancillary to a parallel-group observational prospective study which was approved by the medical local ethics committee (protocol number DDG 334/19-06-2019).
Sections du résumé
BACKGROUND
Glucocorticoids (GC) modulate several regulators involved in the pathogenesis of bone changes in rheumatoid arthritis (RA). Trabecular bone score (TBS) allows the indirect assessment of bone quality. The aim of this study was to investigate the effects of GC on TBS and serum levels of bone turnover regulators in patients with recent-onset RA.
MATERIALS AND METHODS
Forty-seven subjects with recent-onset RA (< 6 months) were classified in two groups, low (lGC) and high (hGC) glucocorticoids, according to glucocorticoid dose regimens. Bone mineral density (BMD), TBS, and circulating Dickkopf-1 (Dkk1), sclerostin, osteoprotegerin (OPG), and RANK-L were evaluated at baseline and 6 and 12 months.
RESULTS
BMD significantly declined after 12 months with no significant difference between the lGC and hGC group, whereas TBS decreased in the hGC group only. Circulating OPG decreased during the follow-up period, the reduction being significantly greater in hGC group; conversely, sclerostin and RANK-L serum increased, in a significantly greater extent in the hGC group. TBS inversely correlated with sclerostin, RANK-L, and Dkk1 circulating levels whereas directly correlated with OPG circulating levels. GC cumulative dose showed an inverse relationship with BMD in both the hGC and lGC groups; TBS values showed an inverse relationship with GC cumulative dose in the hGC group only. GC cumulative dose was associated to higher sclerostin and lower OPG serum levels. TBS did not correlate with disease activity whereas BMD was inversely related to disease activity.
CONCLUSIONS
In early RA, GC exposure contributes to the reduction of BMD and affects bone quality depending on dose regimens. TBS could be a useful tool to evaluate the negative effect of GC on bone microarchitecture.
TRIAL REGISTRATION
This study was ancillary to a parallel-group observational prospective study which was approved by the medical local ethics committee (protocol number DDG 334/19-06-2019).
Identifiants
pubmed: 34229744
doi: 10.1186/s13075-021-02562-3
pii: 10.1186/s13075-021-02562-3
pmc: PMC8261978
doi:
Substances chimiques
Glucocorticoids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
180Références
Osteoporos Int. 2015 Jun;26(6):1773-80
pubmed: 25743176
Bone. 2015 Oct;79:259-66
pubmed: 26092650
J Rheumatol. 2004 Aug;31(8):1483-90
pubmed: 15290725
Clin Rheumatol. 2018 Aug;37(8):2169-2178
pubmed: 28551822
Curr Osteoporos Rep. 2014 Mar;12(1):90-7
pubmed: 24488619
Rheumatol Int. 2012 Nov;32(11):3397-403
pubmed: 22057136
Calcif Tissue Int. 2020 Apr;106(4):371-377
pubmed: 31897527
Nat Rev Endocrinol. 2013 Oct;9(10):575-83
pubmed: 23938284
Ann Rheum Dis. 2002 Nov;61 Suppl 2:ii84-6
pubmed: 12379632
Clin Rheumatol. 2005 Apr;24(2):129-33
pubmed: 15372317
Arthritis Rheum. 2008 Jun;58(6):1674-86
pubmed: 18512788
Calcif Tissue Int. 2013 Apr;92(4):354-61
pubmed: 23247536
Osteoporos Int. 2007 Oct;18(10):1319-28
pubmed: 17566815
Joint Bone Spine. 2015 Oct;82(5):320-5
pubmed: 25921803
Scand J Rheumatol. 1996;25(6):367-76
pubmed: 8996471
J Bone Miner Res. 1995 Feb;10(2):257-63
pubmed: 7754805
Ann N Y Acad Sci. 2014 May;1318:41-9
pubmed: 24814757
Curr Rheumatol Rep. 2019 May 23;21(7):34
pubmed: 31123839
RMD Open. 2020 Jan;6(1):
pubmed: 31958273
Osteoporos Int. 2013 Aug;24(8):2191-9
pubmed: 23358608
Ann Rheum Dis. 2009 Mar;68(3):330-6
pubmed: 18375540
J Bone Miner Res. 2012 Nov;27(11):2242-50
pubmed: 22714558
Ann Rheum Dis. 2014 May;73(5):854-60
pubmed: 23520034
Arthritis Rheum. 2002 Jul;46(7):1744-53
pubmed: 12124857
Clin Diabetes Endocrinol. 2018 May 29;4:12
pubmed: 29862042
Lancet. 2016 Oct 22;388(10055):2023-2038
pubmed: 27156434
Joint Bone Spine. 2004 Jan;71(1):9-13
pubmed: 14769514
Arthritis Rheum. 2006 May;54(5):1422-8
pubmed: 16645970
J Intern Med. 1993 Sep;234(3):237-44
pubmed: 8354973
Ann Rheum Dis. 1989 Jul;48(7):535-8
pubmed: 2774695
Rheumatol Int. 1991;11(1):41-4
pubmed: 1866572
J Rheumatol. 1997 Aug;24(8):1495-503
pubmed: 9263141
Bone. 2013 Nov;57(1):272-6
pubmed: 23981659
Biomed Res Int. 2017;2017:4210217
pubmed: 28127556
Clin Exp Rheumatol. 2000 Nov-Dec;18(6):683-90
pubmed: 11138329
Reumatismo. 2014 Jun 28;66(2):125-35
pubmed: 25069494
Front Med (Lausanne). 2020 Nov 23;7:601618
pubmed: 33330566
Biochem Biophys Res Commun. 2005 Apr 1;329(1):177-81
pubmed: 15721290
Ann Rheum Dis. 2020 Jun;79(6):685-699
pubmed: 31969328
Endocrine. 2018 Jul;61(1):7-16
pubmed: 29691807
Arthritis Rheum. 2010 Sep;62(9):2569-81
pubmed: 20872595